Stocksigma LogoStocksigma Logo

Jagsonpal Pharmaceuticals Reports Q2FY27 Results with 29% Consolidated Revenue Growth

Jagsonpal Pharmaceuticals reported consolidated revenue growth of 29% YoY to ₹964 Mn in Q2FY27, driven by 9.3% standalone sales growth (₹814 Mn) and the

Jagsonpal Pharmaceuticals Reports Q2FY27 Results with 29% Consolidated Revenue Growth

Jagsonpal Pharmaceuticals Ltd · Investor Presentation · 29 Oct 2026, 12:18 am

Jagsonpal Pharmaceuticals Reports Q2FY27 Results with 29% Consolidated Revenue Growth Jagsonpal Pharmaceuticals reported consolidated revenue growth of 29% YoY to ₹964 Mn in Q2FY27, driven by 9.3% standalone sales growth (₹814 Mn) and the consolidation of Aequitas Healthcare. Standalone EBITDA reached ₹185 Mn (22.7% margin) with PAT at ₹126 Mn. For H1FY27, standalone revenue rose 9.0% YoY to ₹1,636 Mn, while EBITDA and PAT grew 11.3% and 10.3% to ₹375 Mn and ₹258 Mn, respectively. Following an 85% stake buy in Aequitas and a 200% dividend payout, cash stood at ₹1,347 Mn as of 30th Sep'26.

Original exchange filing (PDF)

More announcements from Jagsonpal Pharmaceuticals Ltd

All Jagsonpal Pharmaceuticals Ltd announcements